+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019

  • ID: 4901351
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 173 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • Galapagos NV
  • ImmunoQure AG
  • MimeTech Srl
  • RemeGen Ltd
  • Samjin Pharm Co Ltd
  • MORE
Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 4, 1, 12, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • Galapagos NV
  • ImmunoQure AG
  • MimeTech Srl
  • RemeGen Ltd
  • Samjin Pharm Co Ltd
  • MORE
Introduction
Report Coverage
Sicca Syndrome (Sjogren) - Overview
Sicca Syndrome (Sjogren) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sicca Syndrome (Sjogren) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
Aldeyra Therapeutics Inc
Alpine Immune Sciences Inc
Atlantic Bio Sci LLC
Bristol-Myers Squibb Co
Eli Lilly and Co
Galapagos NV
Gilead Sciences Inc
GlaxoSmithKline Plc
Ibex Biosciences LLC
Idorsia Pharmaceutical Ltd
ImmunoQure AG
Immunwork Inc
Incyte Corp
MeiraGTx Holdings Plc
MimeTech Srl
Novartis AG
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics
RemeGen Ltd
Resolve Therapeutics LLC
Rise Therapeutics LLC
Rophibio Inc
Samjin Pharm Co Ltd
SinoMab Bioscience Ltd
Spectrix Therapeutics LLC
Suzhou Sinovent Pharmaceuticals Co Ltd
TearSolutions LLC
Viela Bio Inc
Vision Medicines Inc
XTL Biopharmaceuticals Ltd
Sicca Syndrome (Sjogren) - Drug Profiles
Sicca Syndrome (Sjogren) - Dormant Projects
Sicca Syndrome (Sjogren) - Discontinued Products
Sicca Syndrome (Sjogren) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Sicca Syndrome (Sjogren), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Alpine Immune Sciences Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Co, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Co, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Ibex Biosciences LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by ImmunoQure AG, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Incyte Corp, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by MeiraGTx Holdings Plc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by MimeTech Srl, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by OSE Immunotherapeutics, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by RemeGen Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Resolve Therapeutics LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Rise Therapeutics LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Rophibio Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharm Co Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by SinoMab Bioscience Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Spectrix Therapeutics LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by TearSolutions LLC, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Viela Bio Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by Vision Medicines Inc, H2 2019
Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2019
Sicca Syndrome (Sjogren) - Dormant Projects, H2 2019
Sicca Syndrome (Sjogren) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Sicca Syndrome (Sjogren) - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Sicca Syndrome (Sjogren), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aldeyra Therapeutics Inc
  • Alpine Immune Sciences Inc
  • Atlantic Bio Sci LLC
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Galapagos NV
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Ibex Biosciences LLC
  • Idorsia Pharmaceutical Ltd
  • ImmunoQure AG
  • Immunwork Inc
  • Incyte Corp
  • MeiraGTx Holdings Plc
  • MimeTech Srl
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • OSE Immunotherapeutics
  • RemeGen Ltd
  • Resolve Therapeutics LLC
  • Rise Therapeutics LLC
  • Rophibio Inc
  • Samjin Pharm Co Ltd
  • SinoMab Bioscience Ltd
  • Spectrix Therapeutics LLC
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • TearSolutions LLC
  • Viela Bio Inc
  • Vision Medicines Inc
  • XTL Biopharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll